EWG Elevate’s Rigel Pharmaceuticals RIGL Stock Holding History

EWG Elevate’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50	Closed	-$750	–	611
2022 Q4	$750	Buy	+50	New	+$458	﹤0.01%	698

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EWG Elevate's RIGL Position: Q1 2023 in Review

EWG Elevate sold out of Rigel Pharmaceuticals (RIGL) in Q1 2023, closing a stake of 50 shares — an estimated $750 sold.

EWG Elevate first reported a position in RIGL in Q4 2022 and held it in 1 quarter. The position peaked at $750 in Q4 2022. 124 funds tracked by Wall St. Rank hold RIGL as of Q1 2023.

EWG Elevate reported no remaining Rigel Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
EWG Elevate sold 50 Rigel Pharmaceuticals shares in Q1 2023, an estimated $750.
EWG Elevate first reported a position in Rigel Pharmaceuticals in Q4 2022 and held it in 1 quarter.
EWG Elevate's Rigel Pharmaceuticals position peaked at $750 in Q4 2022.
124 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2023.

Based on EWG Elevate's 13F filing for Q1 2023, filed 13 Apr 2023.